Basic Requip Information

• INN (International Nonproprietary Name): Ropinirole.
• Brand Names Available In United Kingdom: Requip; Requip XL; Adartrel in some EU markets; generic ropinirole formulations supplied by multiple manufacturers.
• ATC Code: N04BC04.
• Forms & Dosages: Immediate‑release tablets 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg.
• Forms & Dosages (continued): Extended‑release tablets 2 mg, 4 mg, 6 mg, 8 mg, 12 mg.
• Manufacturers In United Kingdom: Original developer GlaxoSmithKline; generics commonly supplied by Teva, Mylan, Sandoz, Accord and Sun Pharma.
• Registration Status In United Kingdom: Requip is marketed internationally including the UK; EMA approval applies in EU markets and generic ropinirole is widely available—registration relies on national regulatory listings.
• OTC / Rx Classification: Prescription drug (Rx) in all markets.

Latest Research Highlights (UK & EU)

Clinicians often ask whether ropinirole still offers reliable benefit for Parkinson’s disease and restless legs syndrome after the recent studies.

European and UK literature since 2022 continues to support ropinirole’s efficacy for motor symptoms in Parkinson’s disease and for primary restless legs syndrome both as monotherapy and as adjunct therapy.

Extended‑release formulations have been shown to improve adherence by enabling once‑daily dosing compared with immediate‑release schedules.

Meta‑analyses and real‑world studies report similar short‑term motor gains when comparing ropinirole with other non‑ergot dopamine agonists.

Safety signals remain consistent: higher rates of nausea and somnolence during initial titration and persistent reports of hallucinations and compulsive behaviour, notably in older patients, in pharmacovigilance systems.

Regulators have reinforced warnings and clinicians should monitor for impulse control disorders and sudden sleep episodes.

Clinical Effectiveness In The UK

Patients commonly want to know if ropinirole improves daily movement and reduces off‑time.

NHS audit data and clinic reports indicate that ropinirole provides meaningful motor benefit when started early or used as an add‑on to levodopa.

In primary care prescribing datasets and specialist movement‑disorder clinics patients describe reduced off‑time and smoother motor function after careful titration.

Extended‑release (once‑daily) formulations reduce pill burden and the chance of missed doses compared with multiple immediate‑release tablets each day.

Immediate‑release tablets in strengths 0.25 mg to 5 mg are commonly used during titration phases before switching to XR where appropriate.

Key limitations in NHS cohorts include early dropouts due to nausea and sleepiness during titration and likely under‑reporting of impulse control problems.

• Clinician‑reported UPDRS improvement.
• Patient‑reported symptom diaries to monitor off‑time.
• Medication adherence rates improve with XR formulations.

For practice, baseline cognitive and sleep screening are recommended and liaison with Parkinson’s nurse specialists via NHS patient portals improves follow‑up.

Indications And Expanded Uses

Patients often ask what ropinirole is licensed for and where it might be used off‑label.

Parkinson’s Disease

Starting dose: 0.25 mg three times daily.

Titration: increase slowly, typically every week as tolerated.

Maximum: up to 24 mg daily.

Restless Legs Syndrome (RLS)

Starting dose: 0.25 mg once nightly, 1–3 hours before bedtime.

Titration: increase gradually according to symptom control.

Maximum: 4 mg daily.

Off‑Label Uses In NHS Specialist Practice

Occasional specialist use includes dopamine‑responsive dystonia and as a bridge to reduce levodopa dose; these decisions are for specialists and need clear documentation.

Pregnancy And Breastfeeding

Use only if benefits outweigh risks and after specialist advice.

Paediatrics

Not endorsed; safety and efficacy not established for children.

Composition And Brand Landscape

Many people want to know what they will actually receive when their prescription is dispensed.

The active ingredient is ropinirole (INN).

NHS prescribing commonly favours generics for cost savings.

Hospital formularies may list branded options where specific release characteristics are required.

Community pharmacy chains dispense generics via the Electronic Prescription Service (EPS).

Contraindications And Special Precautions

People worry about who should not take ropinirole and what to check before starting.

Absolute contraindication is known hypersensitivity to ropinirole or any excipients.

High‑risk groups include patients with severe hepatic impairment, those with significant renal impairment, elderly patients with polypharmacy, and people with a history of psychosis or hallucinations.

Cardiovascular disease is a concern because of orthostatic hypotension and fall risk.

Patients with prior impulse control disorders need careful assessment and ongoing monitoring.

Driving and operating machinery can be affected because of somnolence and sudden sleep episodes.

Advise abstaining from excessive alcohol during titration because of increased sedation risk.

• Pre‑treatment checklist: medication review for CYP1A2 inhibitors and CNS depressants.
• Pre‑treatment checklist: fall risk and orthostatic blood pressure assessment.
• Pre‑treatment checklist: baseline mental health and impulse control screening.
• Report suspected adverse effects to the MHRA Yellow Card scheme.

Pregnancy and breastfeeding require specialist discussion and risk–benefit assessment.

Dosage Guidelines

Clear dosing reduces side effects and improves outcomes.

For Parkinson’s disease start at 0.25 mg three times daily and increase weekly as tolerated.

Extended‑release options allow once‑daily dosing and can simplify regimens.

For RLS start at 0.25 mg one to three hours before bedtime and titrate slowly up to 4 mg daily.

Elderly patients should start low and titrate more slowly while monitoring blood pressure and cognition.

Severe liver impairment generally contraindicates use and moderate impairment needs cautious dose reduction.

Renal impairment requires specialist guidance for dosing adjustments.

Use EPS for repeat prescriptions and document titration in the GP record so community pharmacists are informed.

Interactions Overview

Patients frequently ask which medicines and foods interfere with ropinirole.

Main pharmacodynamic interactions are additive sedation with opioids, benzodiazepines, antipsychotics and alcohol.

CYP1A2 metabolism is clinically relevant.

Strong CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin can raise ropinirole levels and increase adverse effects.

Enzyme inducers, including cigarette smoking and some antiepileptics like carbamazepine, can reduce ropinirole exposure and effectiveness.

MHRA Yellow Card reports have highlighted interactions with antidepressants and antipsychotics leading to increased neuropsychiatric events.

Advise patients not to start or stop smoking, or to begin interacting medicines, without clinical review.

Cultural Perceptions And Patient Habits

Patients and carers seek lived experience before starting therapy.

Online forums such as Parkinson’s UK forums, Patient.info and Mumsnet often discuss nausea at initiation, daytime sleepiness, and impulse control changes.

Community pharmacists in chains like Boots and LloydsPharmacy are trusted for counselling and commonly clarify dosing and side‑effect management.

NHS 111 is frequently used for urgent advice about troubling side effects.

Many patients are comfortable with online pharmacies and e‑prescriptions but still value face‑to‑face counselling, especially carers of people with Parkinson’s disease.

• Common concerns: nausea, sleep attacks, and new gambling or binge eating urges.
• Typical coping strategies: slow titration and taking a small snack with the tablet to reduce nausea.
• Where to seek help: GP, Parkinson’s nurse, community pharmacist, or NHS 111 for urgent issues.

Stigma around impulse control problems can delay reporting, so proactive questioning is advised during follow‑up.

Availability And Pricing Patterns

People frequently ask where they can get their prescription and what it will cost.

Ropinirole immediate‑release and extended‑release tablets are stocked across major UK chains and community pharmacies.

Generics dominate primary care dispensing and are preferred on cost grounds by NHS prescribers.

Prescription charges vary across the UK: Scotland and Wales have free NHS prescriptions.

In England there is a standard prescription charge per item unless the patient is exempt.

Northern Ireland follows its own arrangements for prescription charges.

Private purchase via online pharmacies is possible but prescribers must follow MHRA guidance.

In our online pharmacy, requip is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

EPS and repeat dispensing make ongoing access easier for stable patients.

Hospital outpatient supplies may favour a specific branded formulation if listed on the formulary.

Comparable Medicines And Prescribing Preferences

Clinicians weigh ropinirole against other dopamine agonists and levodopa options.

Common alternatives on NHS formularies include pramipexole, rotigotine patch and levodopa preparations.

Advantages of ropinirole include established effectiveness for PD and RLS, availability of extended‑release once‑daily tablets and cost savings with generics.

Drawbacks include early nausea, somnolence and the risk of impulse control disorders.

• Efficacy: Similar motor benefit to other non‑ergot dopamine agonists in short‑term studies.
• Side‑effect profile: Nausea and somnolence are common during titration.
• Dosing frequency: XR offers once‑daily convenience; IR used for titration.
• Route: Rotigotine patch offers an alternative for swallowing issues.
• Cost: Generics usually preferred by the NHS.

NHS decision cues include patient preference, comorbidity profile, pill burden and prior tolerance of dopamine agonists.

Frequently Asked Questions

• Will I feel sick when I start ropinirole? Many patients do experience nausea during titration; taking the dose with food and increasing the dose slowly reduces this risk.
• Can I drive? Do not drive until you know how ropinirole affects you and report sudden sleepiness to your GP and the DVLA if it persists.
• What about impulse control problems? Report any new compulsive behaviours such as gambling or binge eating immediately so the clinician can review the dose or consider switching.
• Can I stop it suddenly? You should not stop ropinirole abruptly; consult your prescriber for a safe tapering plan.

Signpost to NHS resources such as Parkinson’s nurse services, NHS 111 and the MHRA Yellow Card reporting system for adverse events.

Guidelines For Proper Use

Pharmacist counselling helps patients use ropinirole safely and stick to treatment.

• Confirm indication and whether the prescription is for Parkinson’s disease or restless legs syndrome.
• Review allergies and confirm no known hypersensitivity to ropinirole or excipients.
• Check current medicines for CYP1A2 inhibitors, inducers and CNS depressants.
• Explain the titration schedule and advise what to do if a dose is missed.
• Warn about somnolence, sudden sleep episodes and impulse control issues and advise who to contact.
• Document counselling in EPS notes and encourage use of NHS portals to track prescriptions and symptoms.

Storage advice: store tablets at 20–25°C, protect them from light and moisture and keep them out of reach of children.

Community pharmacists should schedule follow‑up within 2–4 weeks after initiation for high‑risk patients.

Delivery Across United Kingdom